The medical community of research technology finally has initiated the monoclonal antibody specific for a particular tumor-related antigen with the man made cytotoxic cell-killing agents. This is connected by linker systems formed to bind the cytotoxic agent to the antibody, then releasing the agent within its targeted cell. This procedure is intended to spare non-targeted cells from being destroyed, which eliminates many toxic effects of traditional chemotherapy yet positively enhancing antitumor activity.
Genetics’ most important near-term milestone is the FDA approval decision in the post-transplant treatment consolidation of Hodgkin Lymphoma patients with high risk for relapse or the progression of the disease. Half of these patients undergoing autologous stem cell transplant are high risk without any therapeutic advances improving the prognosis. Therefore,the strong package submitted to the FDA was exciting to the point of amazing, as the genetics community celebrated the FDA decision regarding the Seattle Genetics supplemental BLA on or before August 18, 2016.
2nd Success in Form of Partnership
Seattle Genetics founder and CEO Clay Siegall announced in a new press release a 25 Million Dollar licensing partnership with Unum as an extension of the company’s 17 year work history in cancer research. Seattle Genetics’ theory for “Unum’s innovative technology proposal is development of universal, antibody-directed immunotherapy of cells. This is different from previously engineered approaches regarding T-cells, and should have applicability through cancer targets across the board. This is considered a collaboration between two of the most promising companies in cellular immunotherapy, and the purpose is to develop new treatment options for those cancer patients who have endured unmet medical needs.
The consolidated companies will initially develop two products incorporating Seattle Genetics’ antibodies. Seattle Genetics also has the scientific option to expand the partnership collaboration to include a third product. The companies will split profits 50/50 on co-developed drugs in the U.S. and Seattle Genetics also will keep exclusive commercial rights outside of the United States, with payment to Unum of agreed upon high royalties.